Earnings ·
Reports Q3 net loss of €76.0 million and $536.3M cash balance as SUPRAME enrollment nears completion
IMTXImmatics N.V.
Immatics N.V. reported a net loss of €76.0 million for the third quarter ended September 30, 2026, compared to a €50.5 million loss in the prior-year period. Revenue from collaboration agreements rose to €6.9 million, driven by higher milestone payments and activity levels. Research and development expenses increased to €70.3 million due to costs associated with the ongoing SUPRAME Phase 3 trial for anzu-cel. The company ended the quarter with $536.3 million in cash and other financial assets, extending its projected cash runway into Q4 2028. Enrollment in the SUPRAME trial is on track to complete randomizations by year-end, with top-line data expected in H1 2027. Additionally, updated Phase 1 data for IMA203CD8 and IMA402 were presented at ESMO Congress 2026, showing encouraging anti-tumor activity. Immatics is a clinical-stage biotechnology company focused on developing precision cancer therapies targeting the PRAME antigen.